This week, mass compounding closed for tirzepatide, EMR's emerged as a new GLP-1 gatekeeper, and the Trump administration set sights on benchmark drug pricing.
Yes!
I’m hopeful 🤞🏼🤞🏼that this will “stick” in more ways than one 😉.
This gives me hope for when my compound stock is depleted in October and I have to figure out my next steps 🤞🤞
Yes!
I’m hopeful 🤞🏼🤞🏼that this will “stick” in more ways than one 😉.
This gives me hope for when my compound stock is depleted in October and I have to figure out my next steps 🤞🤞